During the past 15 years, genomic analysis for selection of molecularly guided targeted therapy has become standard of care for a wide range of advanced solid tumors including non–small cell lung cancer (NSCLC) (eg, EGFR, ALK, ROS1), colorectal cancer (eg, KRAS, BRAF), breast cancer (eg, PIK3CA), and urothelial carcinoma (eg, FGFR2/3), with emerging targets being studied across a range of cancers. This has led to a growing array of available targeted therapies and a parallel increase in the number and diversity of molecular diagnostic tests to help with treatment selection. Tumor sequencing not only helps to inform which treatments are likely to be effective but also point to which therapies should not be used (eg, EGFR antibodies in KRAS-mutant colon cancer, immune checkpoint inhibitors in EGFR or ALK-positive NSCLC).
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Oxnard GR, West H, King JC. Improving Molecular Oncology by Making Results Available to Patients. JAMA Oncol. 2019;5(12):1689–1690. doi:10.1001/jamaoncol.2019.4390
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: